Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
- PMID: 29958900
- DOI: 10.1016/j.mam.2018.06.003
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Abstract
Fibrosis denotes excessive scarring, which exceeds the normal wound healing response to injury in many tissues. Although the extracellular matrix deposition appears unstructured disrupting the normal tissue architecture and subsequently impairing proper organ function, fibrogenesis is a highly orchestrated process determined by defined sequences of molecular signals and cellular response mechanisms. Persistent injury and parenchymal cell death provokes tissue inflammation, macrophage activation and immune cell infiltration. The release of biologically highly active soluble mediators (alarmins, cytokines, chemokines) lead to the local activation of collagen producing mesenchymal cells such as pericytes, myofibroblasts or Gli1 positive mesenchymal stem cell-like cells, to a transition of various cell types into myofibroblasts as well as to the recruitment of fibroblast precursors. Clinical observations and experimental models highlighted that fibrosis is not a one-way road. Specific mechanistic principles of fibrosis regression involve the resolution of chronic tissue injury, the shift of inflammatory processes towards recovery, deactivation of myofibroblasts and finally fibrolysis of excess matrix scaffold. The thorough understanding of common principles of fibrogenic molecular signals and cellular mechanisms in various organs - such as liver, kidney, lung, heart or skin - is the basis for developing improved diagnostics including biomarkers or imaging techniques and novel antifibrotic therapeutics.
Keywords: Biomarkers; Exosome; Fibroblasts; Imaging; Macrophage; Matrix; Organ fibrosis; Regression; Therapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.Mol Aspects Med. 2019 Feb;65:70-99. doi: 10.1016/j.mam.2018.07.001. Epub 2018 Aug 2. Mol Aspects Med. 2019. PMID: 30056242 Review.
-
IL-33/ST2 Axis in Organ Fibrosis.Front Immunol. 2018 Oct 24;9:2432. doi: 10.3389/fimmu.2018.02432. eCollection 2018. Front Immunol. 2018. PMID: 30405626 Free PMC article. Review.
-
Human Fibrotic Diseases: Current Challenges in Fibrosis Research.Methods Mol Biol. 2017;1627:1-23. doi: 10.1007/978-1-4939-7113-8_1. Methods Mol Biol. 2017. PMID: 28836191 Review.
-
Intestinal fibrosis.Mol Aspects Med. 2019 Feb;65:100-109. doi: 10.1016/j.mam.2018.10.003. Epub 2018 Nov 2. Mol Aspects Med. 2019. PMID: 30385174 Review.
-
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies.Mol Aspects Med. 2023 Aug;92:101191. doi: 10.1016/j.mam.2023.101191. Epub 2023 May 24. Mol Aspects Med. 2023. PMID: 37236017 Review.
Cited by
-
Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy.Front Bioeng Biotechnol. 2022 Sep 15;10:988683. doi: 10.3389/fbioe.2022.988683. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36185428 Free PMC article.
-
IFN-α-2b Reduces Postoperative Arthrofibrosis in Rats by Inhibiting Fibroblast Proliferation and Migration through STAT1/p21 Signaling Pathway.Mediators Inflamm. 2023 Mar 4;2023:1699946. doi: 10.1155/2023/1699946. eCollection 2023. Mediators Inflamm. 2023. PMID: 36915717 Free PMC article.
-
The Role of Extracellular Vesicles in Idiopathic Pulmonary Fibrosis Progression: An Approach on Their Therapeutics Potential.Cells. 2022 Feb 11;11(4):630. doi: 10.3390/cells11040630. Cells. 2022. PMID: 35203281 Free PMC article. Review.
-
Rapamycin Upregulates Connective Tissue Growth Factor Expression in Hepatic Progenitor Cells Through TGF-β-Smad2 Dependent Signaling.Front Pharmacol. 2018 Aug 8;9:877. doi: 10.3389/fphar.2018.00877. eCollection 2018. Front Pharmacol. 2018. PMID: 30135653 Free PMC article.
-
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.Front Immunol. 2022 Jul 20;13:935779. doi: 10.3389/fimmu.2022.935779. eCollection 2022. Front Immunol. 2022. PMID: 35967342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources